Highlights from the ESH 2016 3rd International Conference on Multiple Myeloma
Release Date: December 05, 2016
Expiration Date: December 05, 2017
Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.
Our expert Managing Myeloma faculty members provide key highlights from the recently held 3rd International Conference on Multiple Myeloma, hosted and coordinated by the European School of Haematology (ESH). This activity provides insights from conference presenters and covers aspects from more than 10 hours of content focused on the biology of myeloma and the impact of clonal evolution on therapeutic strategies, advances in the diagnosis and staging of disease, treatment strategies and practice pearls related to supportive care for elderly patients, and the evolving therapeutic landscape for relapsed multiple myeloma. Listen today and be up to date on the latest information coming out of Milan.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Evaluate the most significant findings from clinical trials in multiple myeloma as presented at the ESH 3rd International Conference on Multiple Myeloma
- Describe how emerging data about diagnosis, assessment, and treatment of multiple myeloma are relevant to practicing clinicians and how this data may be incorporated into clinical practice
Introduction – Sagar Lonial, MD, FACP– Moderator
Biology – Nikhil C. Munshi, MD
Myeloma Diagnosis and Staging (including MGUS and SMM) – María-Victoria Mateos, MD, PhD
Treatment of Elderly Patients – Heinz Ludwig, MD
Treatment of Relapsed Patients – Thierry Facon, MD
Instructions for Participation and Credit
This activity is eligible for credit through December 5, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.
Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
Thierry Facon, MD
Professor of Haematology
Department of Haematology
Lille University Hospital
Dr. Thierry Facon received his medical degree at Lille University School of Medicine. He is Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, a position he has held since 2000. He is also an honorary professor at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, China.
Dr. Facon is a member of the American Society of Hematology (ASH), the International Myeloma Working Group (IMWG), the International Myeloma Foundation (IMF), and is a founding member and administrator of the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG). In addition, he was president of the Intergroupe Francophone du Myélome (IFM), and vice president of the French Society of Haematology. Dr. Facon has presented at international congresses, including the plenary sessions at the annual meeting of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH), and the educational sessions of European Haematology Association (EHA) and ASH. He also co-organized the XIIIth International Myeloma Workshop (IMW) in Paris. Dr. Facon has authored a number of articles and has published his work in various journals including The Lancet and The New England Journal of Medicine.
Heinz Ludwig, MD
Professor of Internal Medicine and Haemato-Oncology
Wilhelminen Cancer Research Institute
Dr. Heinz Ludwig is Professor of Internal Medicine and Haemato-Oncology and chairs the Wilhelminen Cancer Research Institute at the Department of Medicine I, Centre for Oncology and Haematology, Wilhelminenspital, Vienna, Austria.
Dr. Ludwig has served as president of ESMO and is on the board of international directors of ASCO. At present, he is a member of the board of the International Myeloma Foundation, of the National Health Council of Vienna, and president of the Austrian Forum Against Cancer. In addition, Dr. Ludwig serves as peer reviewer of several international journals and has published a large number of scientific articles. He is a strong supporter of patient’s interests and patient’s rights. Under his initiative, an international charter of cancer patient’s rights has been published under the auspices of ASCO, the Chinese Society of Clinical Oncology (CISCO), and ESMO.
Dr. Ludwig’s research interests span the field of therapeutics in hematology and medical oncology. His research focuses on the biological and clinical aspects of multiple myeloma (MM), as well as on the analysis of factors associated with anemia and the treatment of anemia in cancer patients. He led several investigator sponsored clinical trials in MM and participated in many studies. Within the International Myeloma Working Group, he has contributed to several position papers. Presently, his team is evaluating the role of certain signal transduction molecule inhibitors in MM cell lines and in MM bearing mice. Furthermore, he is running academic trials with ixazomib and others with carfilzomib-combination regimens and is participating in several international studies.
María-Victoria Mateos, MD, PhD
Associate Professor of Medicine
University of Salamanca
Dr. María-Victoria Mateos received her medical degree from the University of Valladolid in Spain and completed her residency in hematology at the University Hospital of Salamanca, where she also completed a doctoral degree. She is a consultant physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. In addition, she is the Director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Hematology Department.
Dr. Mateos is a member of the International Myeloma Working Group (IMWG), International Myeloma Society (IMS), and has served on the European Hematology Association (EHA) Scientific Program Committee and Advisory Board, and the American Society of Hematology (ASH) Scientific Committee on plasma cell diseases. She is a Councillor on the EHA Board, a member of the Steering Committee for the Society of Hematologic Oncology (SOHO), the International Myeloma Society (IMS) board, and the European School of Haematology (ESH) Scientific Committee. In addition, Dr. Mateos serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smoldering multiple myeloma patients that have profoundly influenced current options for treating these patient populations.
Dr. Mateos has published over 140 papers in peer-reviewed international journals, some of which have become key references in the multiple myeloma field. She is associate editor of myeloma in Annals of Haematology, and is a reviewer for journals such as The New England Journal of Medicine, Lancet, and Lancet Oncology.
Nikhil C. Munshi, MD
Professor of Medicine
Department of Medicine
Harvard Medical School
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University and Shri Sayaji General Hospital in Baroda, India. He completed a medical oncology research fellowship at Johns Hopkins Oncology Center before receiving a clinical fellowship in hematology/oncology at Indiana University Medical Center. Dr. Munshi is Professor of Medicine at Harvard Medical School, the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana Farber Cancer Institute. In addition, he is an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare System, Harvard Medical School.
Dr. Munshi has organized and chaired numerous guideline panels to develop consensus recommendations for management of myeloma. He serves as a co-chair of the National Steering Committee on Myeloma (National Cancer Institute), is member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee, and is a founding member and vice-president of the International Myeloma Society. Dr. Munshi has written more than 400 peer-reviewed publications and has contributed chapters on plasma cell neoplasms in Harrison’s Principles of Internal Medicine; DeVita’s Principles and Practice of Oncology, and Hoffman’s Hematology: Basic Principles and Practice. He received a Leukemia Society of America Scholar in Translational Research and the Waldenström’s Award for the most Distinguished Lifetime Achievement in Myeloma Research in 2013.
A recognized international leader in translational research in multiple myeloma, Dr. Munshi’s focus spans both basic sciences to understand molecular mechanisms driving the genomic instability to translational approaches directed at improving diagnosis and prognosis, as well as therapeutics including novel antigen-directed immunotherapy/vaccine approaches and small molecules for myeloma. His research has provided pivotal understanding of genomic changes in myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-129-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: Program Number: 16-129-045
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Onyx, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Celgene, Janssen, and Takeda Oncology.
Dr. Heinz Ludwig has received honoraria related to formal advisory activities from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, and Janssen-Cilag Limited, as well as speakers’ bureau activities from Amgen, Celgene, Janssen-Cilag, and Takeda Oncology. He has received grant support related to research activities from Amgen and Takeda Oncology.
Dr. Thierry Facon has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology, as well as speakers’ bureau activities from Celgene, Janssen, and Takeda Oncology.
Dr. María-Victoria Mateos has received honoraria related to speakers’ bureau activities and formal advisory activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology, in addition to formal advisory activities from Bristol-Myers Squibb Company.
Dr. Nikhil Munshi has received honoraria as a consultant from Celgene Corporation, Merck & Co., Inc., OncoPep, and Takeda Oncology.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.